furaprevir (TG-2349) / TaiGen - LARVOL DELTA

Safety, tolerability, pharmacokinetics and effects of gene polymorphisms on Furaprevir (TG-2349), a novel hepatitis C inhibitor: a randomized phase Ι study. (PubMed, Pharmacology) - "Food significantly impacts the bioavailability of furaprevir. Furaprevir does not accumulate in vivo after multiple rising doses and has demonstrated safety and tolerability in healthy subjects, supporting its further investigation in patients with hepatitis C."

Journal • PK/PD data • Hepatitis C • Hepatology • Infectious Disease • Inflammation • CYP3A4 • CYP3A5

To Evaluate Efficacy and Safety in TG-2349 Combination With DAG181 (± Ribavirin) in HCV Genotype I Infected Patients (clinicaltrials.gov) - P2; N=133; Completed; Sponsor: Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.; Recruiting ➔ Completed

Clinical • Trial completion • Fibrosis • Hepatitis C Virus • Hepatology • Immunology

A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and RBV for HCV Type I Patients (clinicaltrials.gov) - P3; N=370; Completed; Sponsor: Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.; Recruiting ➔ Completed

Clinical • Combination therapy • Trial completion • Fibrosis • Hepatitis C Virus • Hepatology • Immunology • AFP • ALB

A Study to Evaluate the Efficacy and Safety of TG-2349 in Combination With Peg-interferon and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1b Infection (clinicaltrials.gov) - P2; N=48; Not yet recruiting; Sponsor: TaiGen Biotechnology Co., Ltd.

New P2 trial • Biosimilar • Fibrosis • Hepatitis C Virus • Immunology • Inflammation

A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and RBV for HCV Type I Patients (clinicaltrials.gov) - P3; N=360; Recruiting; Sponsor: Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.

Clinical • Combination therapy • New P3 trial